Corpus overview


MeSH Disease

Human Phenotype


There are no transmission terms in the subcorpus

    displaying 1 - 4 records in total 4
    records per page

    Olfactory and gustatory dysfunction MESHD in 2019 novel coronavirus: An updated systematic review and meta-analysis

    Authors: Marzieh Esmaeili; Fatemeh Abdi; Gita Shafiee; Hadis Rastad; Hamid Asayesh; Zahra Esmaeili Abdar; Fereshteh Baygi; Mostafa Qorbani

    doi:10.21203/ Date: 2020-07-17 Source: ResearchSquare

    BackgroundEvidence showed that partial or complete loss of smell and taste might be a possible primary symptom of the 2019 novel coronavirus (COVID-19). This study aimed to systematically review and pool all available evidence on the olfactory and gustatory dysfunction MESHD in COVID-19 patients. MethodsIn this systematic review, a comprehensive search was carried out systematically through e-databases including PubMed, EMBASE, Scopus, and Web of Science (WoS); that was limited to English-language studies published from 2019 up to 6th May 2020. Afterward, all studies reported the taste and smell dysfunction in the COVID-19 patients were included. The quality of the studies was assessed by the Mixed Methods Appraisal Tool (MMAT). The pooled prevalence SERO of olfactory and gustatory dysfunction MESHD was estimated using the random effects meta-analysis method.ResultsAmong 28 eligible included studies in this systematic review, finally, 22 studies met the eligibility criteria and were included in the meta-analysis. According to the random effect meta-analysis, the global pooled prevalence SERO (95% confidence interval) of any olfactory dysfunction MESHD, anosmia HP anosmia MESHD, and hyposmia HP was 55% (40%-70%), 40% (22%-57%), and 40% (20%-61%) respectively. The pooled estimated prevalence SERO of any gustatory dysfunction MESHD, ageusia, and dysgeusia MESHD was 41% (23%-59%), 31% (3%-59%), and 34% (19%-48%) respectively. ConclusionOlfactory and gustatory dysfunction MESHD is prevalent among COVID-19 patients. Therefore, olfactory and gustatory dysfunction MESHD seems to be part of important symptoms and notify for the diagnosis of COVID-19, especially in the early phase of the infection MESHD.

    Prevalence SERO and Recovery of Olfactory Dysfunction in 1,363 patients with coronavirus disease MESHD 2019: A Multicenter Longitudinal Study.

    Authors: Jerome Lechien; Carlos Chiesa-Estomba; Eline Beckers; Vincent Mustin; Morgane Ducarme; Fabrice Journe; Arnaud Marchant; Lionel Jouffe; Maria Barillari; Stephane Hans; Sven Saussez

    doi:10.21203/ Date: 2020-06-29 Source: ResearchSquare

    Olfactory dysfunction MESHD ( OD MESHD) is a key symptom of coronavirus disease MESHD 2019 (COVID-19). Currently, a few data are available about the recovery of OD MESHD after the infection resolution. In this study, we investigated both prevalence SERO and recovery rate of OD MESHD with subjective and objective clinical tools in 2,581 patients. First, our data showed that the prevalence SERO of OD MESHD was significantly higher in mild form (85.9%) compared with moderate-to-critical forms (4.5-9.7%; p=0.001). Second, focusing on patients with OD MESHD who completed the 2-month follow-up period (N=1,363), we observed that 328 patients (24.1%) did not subjectively recover olfaction 60 days after the onset of the dysfunction. The mean duration of self-reported OD MESHD was 21.6±17.9 days. Third, the objective olfactory evaluations performed on a subset of patients (N=233) reported hyposmia HP or anosmia HP anosmia MESHD in 54.7% and 36.6% of mild and moderate-to-critical forms, respectively (p=0.001). At the end of follow-up, 15.3% of anosmic/hyposmic patients did not objectively recover olfaction. The higher baseline severity of objective olfactory evaluations was strongly predictive of persistent OD MESHD (p<0.001). OD MESHD disappeared in 75% to 85% of patients regarding self-reported or objective olfactory evaluations.

    Sudden Onset, Acute Loss of Taste MESHD and Smell in Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review

    Authors: Lakshman SAMARANAYAKE; Kausar Fakhruddin; Chamila Panduwawala

    id:10.20944/preprints202006.0198.v1 Date: 2020-06-16 Source:

    Early detection, isolation, and management of COVID-19 patients are crucial to contain the current pandemic. The CDC in USA recently included "sudden loss of taste MESHD ( dysgeusia/ageusia MESHD) and smell ( anosmia HP anosmia MESHD/ hyposmia HP)” as symptoms of COVID-19. If these symptoms are reliable forerunner symptoms of COVID-19, then it may facilitate early detection and containment of the disease. Hence, we systematically evaluated the contemporary evidence on dysgeusia MESHD and anosmia HP anosmia MESHD as trigger symptoms in COVID-19. Ovid MEDLINE, EBSCO host, and Web of Science databases were searched between December 25, 2019-May 30, 2020.Of the 13 identified records, eight (totaling 11,054 COVID-19 patients), were included, as per the selection criteria. The studies emanated mostly from the European community, as well as China, the USA, and Iran. In total, anosmia HP anosmia and dysgeusia symptoms MESHD were present in 74.9 % and 81.3% ambulatory as well as hospitalized, mild-to-severe cases of COVID-19 patients, respectively. The European, US, and Iran data indicate that olfactory, and gustatory symptoms appear prior to general COVID-19 symptoms in a majority of the patients. To our knowledge, this is the first systematic review analyzing the prevalence SERO of chemosensory dysfunction MESHD in COVID-19. Further, studies are essential to evaluate their utility as harbingers of COVID-19 onset, and to establish clinical practice guidelines.

    Psychophysical Olfactory Findings of Mild-to-moderate COVID-19 Patients: Preliminary Report.

    Authors: Jerome R. Lechien; sven saussez; Pierre Cabaraux; Stephane Hans; Mohamad Khalife; Delphine Martiny; Carlos Chiesa

    doi:10.1101/2020.05.02.20070581 Date: 2020-05-06 Source: medRxiv

    Since the onset of the COVID-19 infection MESHD, many patients reported sudden loss of smell ( SLS MESHD). However, due to the lack of psychophysical testings, it remains difficult to know if these patients really have hyposmia HP hyposmia MESHD or anosmia HP. Our group investigated the prevalence SERO of anosmia HP anosmia MESHD and hyposmia HP in 28 COVID-19 patients and the potential association with nasal complaints.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.